BioXell reports top-line OAB Phase IIb results

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Milan, Italy, April 8, 2009 - BioXell S.p.A. (SIX: BXLN) today
announces top-line results of its Phase IIb trial of Elocalcitol in
patients suffering from Overactive Bladder (OAB).
The urodynamic trial was conducted in 257 patients treated for 4
weeks in a multi-centre, double blind, placebo controlled study. A
statistically significant effect on the primary endpoint, the 'change
in volume at first involuntary contraction', was not achieved. A
statistically significant improvement in 'bladder volume at first
desire to void' was observed in the intention-to-treat population
(ITT). Numerical improvements in most other urodynamic parameters
compared to placebo were observed but did not reach statistical
significance. Numerical improvements were also seen for the key
symptoms of OAB in all treatment groups. A statistically significant
improvement in incontinence episodes was observed in the
modified-intention-to-treat (MITT) population. There was a strong
dose related trend in the improvement in Patient's Perception Bladder
Condition (PPBC) in the ITT population which reached statistical
significance in the per protocol (PP) analysis.
"The results on the primary endpoint are disappointing," remarks
Francesco Sinigaglia, CEO, "Data on the secondary endpoints are
encouraging and we will be discussing the full data set with our
experts and investigators in the coming weeks."
BioXell is currently performing further analyses on the data. A full
analysis of the Elocalcitol OAB data will be presented in the course
of the Annual General Meeting and the Analyst Presentation in Zurich
on April 30, 2009.
To discuss the top-line OAB phase IIb results as well as the 2008
Financial Results (to be published on April 9, 2009), BioXell will
hold a:

Conference call on Thursday, April 9, 2009 at 10.00am CET
To participate in the conference call, please dial +41 (0) 22 592
7312 (Europe & CH), +39 (0) 06 452 108 001 (Italy), +44 207 153 2027
(UK), +1 480 629 1990 (USA)

About BioXell
BioXell (SIX: BXLN) is a biopharmaceutical company focused on the
discovery and development of drugs that exploit novel mechanisms of
action to treat important urological, inflammatory, and related
disorders with significant unmet medical needs. The Company was
founded in 2002 as a spin-out from Roche. BioXell's strategic goal is
to become a fully integrated pharmaceutical Company by maximizing the
commercial potential of its product portfolio and leveraging existing
platforms into profitable partnerships.

In June 2006, BioXell listed its shares on the main segment of the
SIX Swiss Exchange. BioXell approx. employs 40 people and has its
sites in Milan, Italy.

About the OAB Phase IIb trial
The OAB trial was a urodynamic, multi-centre, double-blind, placebo
controlled study in which 257 patients were randomized into three
groups (placebo, 75mcg, 150 mcg), and treated daily for 4 weeks. The
primary endpoint was to evaluate the effect of Elocalcitol on bladder
volume at the first involuntary detrusor contraction, following 4
weeks of treatment. Secondary endpoints included additional
urodynamic parameters, symptoms severity and Patient's Perception of
Bladder Condition. The trial was performed in 47 centres in the
United Kingdom, the Netherlands, Italy and Eastern Europe.
More on BioXell can be found at: www.bioxell.com

For further information, please contact:

BioXell
S.p.A.
Dynamics Group SA
Alvise Sagramoso
Christophe Lamps
Tel: +39 (0)2 210 49
51
Tel: +41 (0)22 308 6222
Fax: +39 (0)2 210 49
529
Fax: +41 (0)22 308 6236
alvise.sagramoso@bioxell.com cla@dynamicsgroup.ch

This press release can be downloaded at www.bioxell.com.
Disclaimer
This press release does not constitute or form part, or all, of any
offer or invitation to sell or issue, or any solicitation of any
offer to purchase or subscribe for, any securities, nor shall part,
or all, of these materials or their distribution form the basis of,
or be relied on in connection with, any contract or investment
decision in relation to any securities. This press release contains
forward-looking statements based on the currently held beliefs and
assumptions of the management of BioXell, which are expressed in good
faith and, in their opinion, reasonable. Forward-looking statements
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition, performance,
or achievements of BioXell, or industry results, to differ materially
from the results, financial condition, performance or achievements
expressed or implied by such forward-looking statements. Given these
risks, uncertainties and other factors, recipients of this document
are cautioned not to place undue reliance on these forward-looking
statements. BioXell disclaims any obligation to update these
forward-looking statements to reflect future events or developments.

--- End of Message ---

bioXell S.p.A
via Olgettina 58 Milan Italy

WKN: A0J3MW; ISIN:
IT0004069933 ;
Listed: Main Market in SIX Swiss Exchange;
Copyright © Hugin AS 2009. All rights reserved.